Valuation
- Market cap
- 845,566,000
- Revenue TTM
- $0
- Net income TTM
- $-148,000,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,146,300
- Avg volume
- 1,610,834
- Day's range
- $10.42 – $10.98
- Shares out
- 79,808,000
- Stochastic %K
- 44%
- Beta
- 0.53
- Analysts
- Strong Sell
- Price target
- $40.60
Company profile
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized a...
Show more
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 908 764 8385
- Website
- https://www.helus.com
- Address
- 100 King Street West, Suite 5600, Toronto, Canada
Latest news
No headlines yet.
